A Phase 2, Non-Comparative, Open-Label, Multicenter, International Study of Medi4736 in Patients with Locally Advanced or Metastatic Pd-L1-Positive Nsclc (Stage Iiib-Iv) Who Have Received ≥ 2 Prior Systemic Treatment Regimens, Including a Platinum-Based Chemotherapy (Atlantic)